Wells Fargo raises Elevance stock price target on Medicaid strength
Wells Fargo raised its price target for Elevance Health (ELV) to $492, citing strong Medicaid and Exchanges performance. The firm increased its 2026 EPS estimate to $30.28, 4.5% above consensus. ELV reported Q3 earnings of $6.99 per share, beating estimates, and raised its full-year outlook. Other analysts also upgraded their price targets for the company.
How this was made
The 30-second read
Why it matters
The upgrade could attract short‑term buying and lift ELV's price toward the new target.
Market read
Analyst target raise provides fresh actionable insight for traders on ELV.
What to watch
Potential regulatory risk in Medicaid funding and competition from other insurers.
Background
The article summarizes Wells Fargo's analyst upgrade following Elevance Health's Q3 earnings beat and revised EPS forecasts.
Ticker impact
Wells Fargo raised its price target on Elevance Health to $492 from $473 after reporting stronger‑than‑expected Q3 results.
likely upward pressure as the market prices in the higher target.
Target increase of ~4% with a 12.5x EPS multiple reflects confidence in Medicaid strength and earnings growth.
Market effects
Positive outlook for health‑insurance sector, especially companies with Medicaid exposure.
U.S. healthcare stocks may see modest gains.
Limited to U.S. markets; no immediate global ripple.
Counterpoint
Target may be overly optimistic if Medicaid policy changes slow growth.
Key entities
- AnalystWells Fargo
Raised price target and EPS estimates for Elevance Health.
- CompanyElevance Health
Health insurer reporting strong Q3 results.
